Harvard/Partners Center for Genetics and Genomics Will Use Affy Arrays in Atherosclerosis Genotyping Study
The Center for Genetics and Genomics of Harvard Medical School and Partners HealthCare will use Affymetrix’s GeneChip Human Mapping microarrays in a genotyping study of atherosclerosis, the two institutions said this week.
HPCGG will obtain the arrays by the end of June under an early access program. In the study, which is funded by the Reynolds Foundation, researchers will genotype more than 1,200 patient samples from the Women’s Health Study, an ongoing NIH study of cardiovascular disease in which 38,000 women participate.
The Human Mapping array is capable of scanning up to 500,000 SNPs, according to Affymetrix.
U. of Cambridge, Cancer Research UK, Perlegen Team Up for Breast Cancer Genotyping Study
Researchers at the University of Cambridge, UK, Cancer Research UK and its technology transfer arm, and Perlegen Sciences will collaborate in a genotyping study to find genetic variations associated with breast cancer, the institutions said this week.
Cancer Research UK provides the funding for the project.
Perlegen Sciences will determine over 200 million genotypes in DNA samples collected from breast cancer patients in the UK and healthy women enrolled in the European Prospective Investigation of Cancer study. Initial results will be validated by Cambridge researchers, who plan to analyze several thousand additional samples.
ABI Restructures Its Marketing, Distribution Pact With Celera
Applera’s board has said Applied Biosystems and Celera Genomics can restructure their 10-year marketing and distribution agreement.
The arrangement allows ABI to exclusively integrate Celera Discovery System data and other genomic and biological information into its product offerings, including TaqMan assays, SNPlex Genotyping Systems, and Expression Array System, in return for royalties based on revenues generated by sales of some products.
Disclosed in an SEC filing this week, the amended agreement increases the royalty rate to 4 percent from 3 percent. The deal also extends the agreement by five years, to the end of the company’s FY 2017.